| ◆英語タイトル：Global Spinal Muscular Atrophy Treatment Market Size study & Forecast, by Product (Nusinersen, Onasemnogen Abeparvovec), by Disease Type (Type 1 SMA, Type 2 SMA, Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Others) and Regional Analysis, 2022-2029
|
 | ◆商品コード：BZW23FE0061
◆発行会社（リサーチ会社）：Bizwit Research & Consulting
◆発行日：2023年1月29日
◆ページ数：約200
◆レポート形式：英語 / PDF
◆納品方法：Eメール（受注後3営業日）
◆調査対象地域：アメリカ、カナダ、イギリス、ドイツ、フランス、スペイン、イタリア、中国、インド、日本、オーストラリア、韓国、ブラジル、メキシコ、中東
◆産業分野：医療
|
◆販売価格オプション
（消費税別）
※
販売価格オプションの説明はこちらで、
ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
Bizwit Research社の本調査レポートでは、2021年に38.8億ドルであった世界の脊髄性筋萎縮症治療市場規模が、2022年から2029年の間に18.6%で拡大すると見込んでいます。本書は、脊髄性筋萎縮症治療の世界市場を徹底調査しており、エグゼクティブサマリー、市場定義・範囲、市場動向、産業分析、リスク分析（新型コロナウイルス感染症の影響）、製品別（ヌシネルセン、オナセムノゲンアベパルボベク）分析、疾患別（1型SMA、2型SMA、その他）分析、流通チャネル別（病院薬局、小売薬局、その他）分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米、その他）分析、競争分析、調査プロセスなどを整理しています。また、本書内には、Biogen、Novartis AG、Ionis Pharmaceuticals Inc.、Biohaven Pharmaceuticals、F. Hoffmann-La Roche Ltd、Cytokinetics、Scholar Rock, Inc.、PTC Therapeutics、NMD PHARMA A/S、Astellas Pharma Inc.などの企業情報が含まれています。
・エグゼクティブサマリー
・市場定義・範囲
・市場動向
・産業分析
・リスク分析（新型コロナウイルス感染症の影響）
・世界の脊髄性筋萎縮症治療市場規模：製品別
- ヌシネルセンの市場規模
- オナセムノゲンアベパルボベクの市場規模
・世界の脊髄性筋萎縮症治療市場規模：疾患別
- 1型SMAにおける市場規模
- 2型SMAにおける市場規模
- その他における市場規模
・世界の脊髄性筋萎縮症治療市場規模：流通チャネル別
- 病院薬局チャネルの市場規模
- 小売薬局チャネルの市場規模
- その他チャネルの市場規模
・世界の脊髄性筋萎縮症治療市場規模：地域別
- 北米の脊髄性筋萎縮症治療市場規模
- ヨーロッパの脊髄性筋萎縮症治療市場規模
- アジア太平洋の脊髄性筋萎縮症治療市場規模
- 中南米の脊髄性筋萎縮症治療市場規模
- その他地域の脊髄性筋萎縮症治療市場規模
・競争分析
・調査プロセス |
Global Spinal Muscular Atrophy Treatment Market is valued at approximately USD 3.88 billion in 2021 and is anticipated to grow with a healthy growth rate of more than 18.6% over the forecast period 2022-2029. Spinal muscular atrophy (SMA) is a type of genetic disease that gradually destroys motor neurons that are the spinal cord and nerve cells in the brain stem. It also affects vital skeletal muscle activity including breathing, walking, speaking, and swallowing, which leads to muscle weakness and atrophy. The growing awareness regarding novel therapies, rising government support, coupled with increasing healthcare expenditure is primary factors that are fostering market growth across the globe.
The prevalence of spinal muscular atrophy is on the rise which is directly associated with the market demand across the globe. The National Organization for Rare Disorders (NORD) estimates that approximately 1 in 10,000 people worldwide suffer with spinal muscular atrophy (SMA). Likewise, according to the Spinal Muscular Atrophy Foundation, the condition is expected to affect 1 in every 6,000 to 10,000 newborns worldwide. Therefore, the growing incidences of the disorder are actively contributing to market demand, which, in turn, fosters the growth of the market. Moreover, the introduction of new product with high efficacies, as well as growing R&D investments are presenting various lucrative opportunities over the forecasting years. However, the high costs associated with the approved products and the dearth of skilled professionals are restricting the market growth throughout the forecast period of 2022-2029.
The key regions considered for the Global Spinal Muscular Atrophy Treatment Market study include Asia Pacific, North America, Europe, Latin America, and the Rest of the World. North America dominated the market in terms of revenue, owing to the growing spending on treatment products and the rising incidence of SMA disorders among the population. Whereas, the Asia Pacific is also expected to grow with the highest CAGR during the forecast period, owing to factors such as rising target populations, increasing expenditure on healthcare services, and geographic expansion of key players in the market space.
Major market players included in this report are:
Biogen
Novartis AG
Ionis Pharmaceuticals Inc.
Biohaven Pharmaceuticals
F. Hoffmann-La Roche Ltd
Cytokinetics
Scholar Rock, Inc.
PTC Therapeutics
NMD PHARMA A/S
Astellas Pharma Inc.
Recent Developments in the Market:
In January 2022, Biogen and Ionis Pharmaceuticals, Inc., declare that the companies entered into licensing agreement with the aim of developing another experimental drug BIIB115 (an antisense oligonucleotide) to cure of patients with SMA. BIIB115 is an experimental preclinical-stage drug. The objective of this agreement is to expand Biogen’s SMA drug portfolio.
In May 2019, Novartis AG announced that its Zolgensma (onasemnogene abeparvovec-xioi) received an approval from the U.S. FDA for the first and only gene therapy for pediatric patients with spinal muscular atrophy (SMA).
Global Spinal Muscular Atrophy Treatment Market Report Scope:
Historical Data 2019-2020-2021
Base Year for Estimation 2021
Forecast period 2022-2029
Report Coverage Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered Product, Disease Type, Distribution Channel, Region
Regional Scope North America; Europe; Asia Pacific; Latin America; Rest of the World
Customization Scope Free report customization (equivalent up to 8 analyst’s working hours) with purchase. Addition or alteration to country, regional & segment scope*
The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.
The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Product:
Nusinersen
Onasemnogen Abeparvovec
By Disease Type:
Type 1 SMA
Type 2 SMA
Others
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Others
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
RoLA
Rest of the World
Chapter 1. Executive Summary
1.1. Market Snapshot
1.2. Global & Segmental Market Estimates & Forecasts, 2019-2029 (USD Billion)
1.2.1. Spinal Muscular Atrophy Treatment Market, by Region, 2019-2029 (USD Billion)
1.2.2. Spinal Muscular Atrophy Treatment Market, by Product, 2019-2029 (USD Billion)
1.2.3. Spinal Muscular Atrophy Treatment Market, by Disease Type, 2019-2029 (USD Billion)
1.2.4. Spinal Muscular Atrophy Treatment Market, by Distribution Channel, 2019-2029 (USD Billion)
1.3. Key Trends
1.4. Estimation Methodology
1.5. Research Assumption
Chapter 2. Global Spinal Muscular Atrophy Treatment Market Definition and Scope
2.1. Objective of the Study
2.2. Market Definition & Scope
2.2.1. Scope of the Study
2.2.2. Industry Evolution
2.3. Years Considered for the Study
2.4. Currency Conversion Rates
Chapter 3. Global Spinal Muscular Atrophy Treatment Market Dynamics
3.1. Spinal Muscular Atrophy Treatment Market Impact Analysis (2019-2029)
3.1.1. Market Drivers
3.1.1.1. Increasing awareness regarding novel therapies
3.1.1.2. Growing prevalence of spinal muscular atrophy
3.1.2. Market Challenges
3.1.2.1. High costs associated with the approved products
3.1.2.2. Dearth of skilled professionals
3.1.3. Market Opportunities
3.1.3.1. Introduction of new product with high efficacies
3.1.3.2. Growing R&D investments
Chapter 4. Global Spinal Muscular Atrophy Treatment Market Industry Analysis
4.1. Porter’s 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.2. Futuristic Approach to Porter’s 5 Force Model (2019-2029)
4.3. PEST Analysis
4.3.1. Political
4.3.2. Economical
4.3.3. Social
4.3.4. Technological
4.4. Top investment opportunity
4.5. Top winning strategies
4.6. Industry Experts Prospective
4.7. Analyst Recommendation & Conclusion
Chapter 5. Risk Assessment: COVID-19 Impact
5.1. Assessment of the overall impact of COVID-19 on the industry
5.2. Pre COVID-19 and post COVID-19 Market scenario
Chapter 6. Global Spinal Muscular Atrophy Treatment Market, by Product
6.1. Market Snapshot
6.2. Global Spinal Muscular Atrophy Treatment Market by Product, Performance – Potential Analysis
6.3. Global Spinal Muscular Atrophy Treatment Market Estimates & Forecasts by Product 2019-2029 (USD Billion)
6.4. Spinal Muscular Atrophy Treatment Market, Sub Segment Analysis
6.4.1. Nusinersen
6.4.2. Onasemnogen Abeparvovec
Chapter 7. Global Spinal Muscular Atrophy Treatment Market, by Disease Type
7.1. Market Snapshot
7.2. Global Spinal Muscular Atrophy Treatment Market by Disease Type, Performance – Potential Analysis
7.3. Global Spinal Muscular Atrophy Treatment Market Estimates & Forecasts by Disease Type 2019-2029 (USD Billion)
7.4. Spinal Muscular Atrophy Treatment Market, Sub Segment Analysis
7.4.1. Type 1 SMA
7.4.2. Type 2 SMA
7.4.3. Others
Chapter 8. Global Spinal Muscular Atrophy Treatment Market, by Distribution Channel
8.1. Market Snapshot
8.2. Global Spinal Muscular Atrophy Treatment Market by Distribution Channel, Performance – Potential Analysis
8.3. Global Spinal Muscular Atrophy Treatment Market Estimates & Forecasts by Distribution Channel 2019-2029 (USD Billion)
8.4. Spinal Muscular Atrophy Treatment Market, Sub Segment Analysis
8.4.1. Hospital Pharmacies
8.4.2. Retail Pharmacies
8.4.3. Others
Chapter 9. Global Spinal Muscular Atrophy Treatment Market, Regional Analysis
9.1. Spinal Muscular Atrophy Treatment Market, Regional Market Snapshot
9.2. North America Spinal Muscular Atrophy Treatment Market
9.2.1. U.S. Spinal Muscular Atrophy Treatment Market
9.2.1.1. Product breakdown estimates & forecasts, 2019-2029
9.2.1.2. Disease Type breakdown estimates & forecasts, 2019-2029
9.2.1.3. Distribution Channel breakdown estimates & forecasts, 2019-2029
9.2.2. Canada Spinal Muscular Atrophy Treatment Market
9.3. Europe Spinal Muscular Atrophy Treatment Market Snapshot
9.3.1. U.K. Spinal Muscular Atrophy Treatment Market
9.3.2. Germany Spinal Muscular Atrophy Treatment Market
9.3.3. France Spinal Muscular Atrophy Treatment Market
9.3.4. Spain Spinal Muscular Atrophy Treatment Market
9.3.5. Italy Spinal Muscular Atrophy Treatment Market
9.3.6. Rest of Europe Spinal Muscular Atrophy Treatment Market
9.4. Asia-Pacific Spinal Muscular Atrophy Treatment Market Snapshot
9.4.1. China Spinal Muscular Atrophy Treatment Market
9.4.2. India Spinal Muscular Atrophy Treatment Market
9.4.3. Japan Spinal Muscular Atrophy Treatment Market
9.4.4. Australia Spinal Muscular Atrophy Treatment Market
9.4.5. South Korea Spinal Muscular Atrophy Treatment Market
9.4.6. Rest of Asia Pacific Spinal Muscular Atrophy Treatment Market
9.5. Latin America Spinal Muscular Atrophy Treatment Market Snapshot
9.5.1. Brazil Spinal Muscular Atrophy Treatment Market
9.5.2. Mexico Spinal Muscular Atrophy Treatment Market
9.5.3. Rest of Latin America Spinal Muscular Atrophy Treatment Market
9.6. Rest of The World Spinal Muscular Atrophy Treatment Market
Chapter 10. Competitive Intelligence
10.1. Top Market Strategies
10.2. Company Profiles
10.2.1. Biogen
10.2.1.1. Key Information
10.2.1.2. Overview
10.2.1.3. Financial (Subject to Data Availability)
10.2.1.4. Product Summary
10.2.1.5. Recent Developments
10.2.2. Novartis AG
10.2.3. Ionis Pharmaceuticals Inc.
10.2.4. Biohaven Pharmaceuticals
10.2.5. F. Hoffmann-La Roche Ltd
10.2.6. Cytokinetics
10.2.7. Scholar Rock, Inc.
10.2.8. PTC Therapeutics
10.2.9. NMD PHARMA A/S
10.2.10. Astellas Pharma Inc.
Chapter 11. Research Process
11.1. Research Process
11.1.1. Data Mining
11.1.2. Analysis
11.1.3. Market Estimation
11.1.4. Validation
11.1.5. Publishing
11.2. Research Attributes
11.3. Research Assumption
❖ 免責事項 ❖http://www.globalresearch.jp/disclaimer